BMS-204352: A potassium channel opener developed for the treatment of stroke

CNS Drug Reviews

Volumn 8, Issue 4, 2002, Pages 353-360

  Jensen, Bo Skaaning ^a  

^a NEUROSEARCH A S   (Denmark)

Author keywords

BK channel; Ca2+ Activated K+ channel; Cerebral ischemia; hSlo channel; Maxi K channel; Neuronal hyperexcitability

Indexed keywords

1 (2 HYDROXY 5 TRIFLUOROMETHYLPHENYL) 5 TRIFLUOROMETHYL 2(3H) BENZIMIDAZOLONE; 1 (5 CHLORO 2 HYDROXYPHENYL) 5 TRIFLUOROMETHYL 2 BENZIMIDAZOLONE; 3 (5 CHLORO 2 METHOXYPHENYL) 3 FLUORO 2,3 DIHYDRO 6 TRIFLUOROMETHYL 1H INDOL 2 ONE; CALCIUM; CALCIUM ACTIVATED POTASSIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; EXCITATORY AMINO ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; POTASSIUM CHANNEL STIMULATING AGENT; VOLTAGE GATED POTASSIUM CHANNEL;

ARTERY OCCLUSION; CALCIUM CELL LEVEL; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; HUMAN; MIDDLE CEREBRAL ARTERY; NERVE CELL EXCITABILITY; NEUROTRANSMITTER RELEASE; NONHUMAN; PSYCHOMOTOR DISORDER; RAT STRAIN; REVIEW; SIDE EFFECT; SPONTANEOUSLY HYPERTENSIVE RAT;

EID: 0036961830     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2002.tb00233.x     Document Type: Review

References (31)

1. American College of Physicians and the Investigators of the PORT Study, 1994. Guidelines for medical treatment for stroke prevention. Ann Intern Med 1994;121:54-55.
2. Bozik ME, Smith JM, Douglass A, et al. POST: double-blind placebo controlled, safety and efficacy trial of intravenous BMS-204352 in patients with acute stroke. Stroke 2000;31:1-270.
3. Bozik ME, Smith JM, Sullivan MA, Braga JM, Warach S, Luby M. POST: Double-blind placebo controlled, safety and efficacy trial of intravenous BMS-204352 in patients with acute stroke. Stroke 2000;31:1-269.
4. Cheney JA, Weisser JD, Bareyre FM, et al. The maxi-K channel opener BMS-204352 attenuates regional cerebral edema and neurologic motor impairment after experimental brain injury. J Cereb Blood Flow Metab 2001;21(4):396-403.
5. Choi DW. Calcium: Still center-stage in hypoxic-ischemic neuronal death. Trends Neurosci 1995;8(2): 58-60.
6. Choi DW. Excitotoxic cell death. J Neurobiol 1992;23(9):1261-1276.
7. Clark WM, Madden KP, Rothlein R, et al. Reduction of central nervous system ischemic injury by monoclonal antibody to intercellular adhesion molecule. J. Neurosurg 1991;75:623-627.
8. De Keyser J, Sutter G, Luiten PG. Clinical trials with neuroprotective drugs in acute ischaemic stroke: Are we doing the right thing? Trends Neurosci 1999;22:535-540.
9. Dupuis DS, Schrøder RL, Jespersen T, et al. Activation of KCNQ5 channels stably expressed in HEK293 cells by BMS-204352. Eur J Pharmacol 2002; In press.
10. Fayad O, Caplik J, Culligan N, et al. Cerebrovasc Dis 2000;10(Suppl 2):71.
11. Frantz SW, Srinivas N, Dominick M, Kelly W, Sanderson T, Schilling B. Safety assessement of BMS-204352, a novel therapeutic agent for the treatment of stroke. Eur J Neurol 2000;7(Suppl 3):P3017.
12. Gold M, Fulmor IE, Srinivas N, Uderman H, Salazar D. BMS-204352: A novel maxi-K potassium opener for the treatment of stroke: Safety and clinical pharmacology in healthy subjects. Ann Neurol 2000;48:3-19.
13. Gribkoff VK, Starrett JE Jr, Dworetzky SI, et al. Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels. Nature Med 2001;(4):471-477.
14. Hallenbeck JM, Dutka AJ. Background review and current concepts of reperfusion injury. Arch Neurol 1990;47:1245-1254.
15. th 2000. San Francisco MED1 320.
16. Hewawasam P, Meanwell NA, Gribkoff VK. 3-substituted oxindole derivatives as potassium channel modulators 1. 1996. Bristol Myers Squibb Co. US Pat. 05565483.
17. Jentsch TJ. Neuronal KCNQ potassium channels: physiology and role in disease. Nat Rev Neurosci 2000;1(1):21-30.
18. Kristian T, Siesjo BK. Calcium in ischemic cell death. Stroke 1998;29(3):705-718.
19. Kwiatkowski TG, Libman RB, Frankel M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med 1999;340(23):1781-1787.
20. McKay MC, Dworetzky SI, Meanwell NA, et al. Opening of large-conductance calcium-activated potassium channels by the substituted benzimidazolone NS004. J Neurophysiol 1994;71(5):1873-1882.
21. + channels by novel benzimidazolone. Eur J Pharmacol 1994;251(1):53-59.
22. + channels in cerebellar granule cells. NeuroReport 1994;5(8):1001-1004.
23. Pendri YR, Martinez EJ, Thottathil JK, Hewawasam P. Preparation of 3-fluoro oxindole derivatives. 1998. Bristol Myers Squibb Co US. Pat. 05808095.
24. + channels in neuronal cells. Eur J Pharmacol 1997;336(2-3):243-249.
25. Salazar DE, Fulmor IE, Srinivas N, Gold M, Uderman H. BMS-204352 - a novel maxi-K potassium opener for the treatment of stroke: Safety and clinical pharmacology in healthy subjects. Eur J Neurol 2000; 7(Suppl 3):S40.
26. Schrøder RL, Jespersen T, Christophersen P, Strøbæk D, Jensen BS, Olesen SP. KCNQ4 channel activation by BMS-204352 and retigabine. Neuropharmacology 2001;40(7):888-898.
27. Shieh CC, Coghlan M, Sullivan JP, Gopalakrishnan M. Potassium channels: Molecular defects, diseases, and therapeutic opportunities. Pharmacol Rev 2000;52(4):557-594.
28. Starrett JE, Kiesewetter DO, Jagoda EM, et al. Brain uptake and biodistribution studies in rats of the maxi-K channel opener BMS-204352: A potential neuroprotectant for the treatment of acute stroke. Ann Neurol 2000;48:3-153.
29. 2+. Neuropharmacology 1996;35(7):903-914.
30. Sudlow CL, Warlow CP. Comparable studies of the incidence of stroke and its pathological types: results from an international collaboration. International Stroke Incidence Collaboration. Stroke 1997;28:491-499.
31. Zipfel GJ, Lee JM, Choi DW. Reducing calcium overload in the ischemic brain. N Engl J Med 1999;341(20):1543-1544.